{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:28:14Z","timestamp":1793104094441,"version":"4.5.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.exphem.2026.105384","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T22:45:55Z","timestamp":1769985955000},"page":"105384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block"],"prefix":"10.1016","volume":"158","author":[{"given":"Fucai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105384_bib0001","unstructured":"AUCATZYL: the FDA, 2024. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl. Accessed February 24, 2026"},{"key":"10.1016\/j.exphem.2026.105384_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0005","unstructured":"FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia: the FDA, Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic Accessed October 1, 2021."},{"key":"10.1016\/j.exphem.2026.105384_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0008","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2026.105384_bib0009","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2026.105384_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","article-title":"Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy","volume":"44","author":"Zhang","year":"2024","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.exphem.2026.105384_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \"off-the-shelf\" CAR-T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2026.105384_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155518","article-title":"Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: a comprehensive review","volume":"262","author":"Tang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.exphem.2026.105384_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1464218","article-title":"CAR-macrophage: breaking new ground in cellular immunotherapy","volume":"12","author":"Huang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1491282","article-title":"Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects","volume":"12","author":"Alidadi","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41577-024-01081-x","article-title":"Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease","volume":"25","author":"Tiwari","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105384_bib0019","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/sj.gt.3302706","article-title":"Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo","volume":"13","author":"Biglari","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2026.105384_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: a new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2026.105384_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0024","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0026","article-title":"CAR-macrophages: tailoring cancer immunotherapy","volume":"15","author":"Chettri","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0027","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2026.105384_bib0028","article-title":"Photoresponsive vaccine-like CAR-M system with high-efficiency central immune regulation for inflammation-related depression","volume":"34","author":"Liu","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.exphem.2026.105384_bib0029","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","article-title":"Advances in engineered macrophages: a new frontier in cancer immunotherapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.exphem.2026.105384_bib0030","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105384_bib0031","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41586-023-06002-x","article-title":"Physiology and diseases of tissue-resident macrophages","volume":"618","author":"Lazarov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105384_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1475369","article-title":"Developmental programming of tissue-resident macrophages","volume":"15","author":"Viola","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0033","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ijms26031272","article-title":"Unveiling the phenotypic variability of macrophages: insights from donor diversity and pooling strategies","volume":"26","author":"Taciak","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122683","article-title":"The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods","volume":"348","author":"Metanat","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0035","article-title":"Macrophage-centered therapy strategies: a promising weapon in cancer immunotherapy","author":"Wang","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","article-title":"Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets","volume":"10","author":"Guan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0037","article-title":"SAMHD1 knockout hiPSC model enables high lentiviral transduction efficiency in myeloid cell types","volume":"16","author":"Li","year":"2025","journal-title":"Front Genet"},{"key":"10.1016\/j.exphem.2026.105384_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116925","article-title":"Engineering macrophages and their derivatives: a new hope for antitumor therapy","volume":"177","author":"Wei","year":"2024","journal-title":"Biomed Pharmacothe"},{"key":"10.1016\/j.exphem.2026.105384_bib0039","article-title":"Engineering human circulating monocytes\/macrophages by systemic deliverable gene editing","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1457323","article-title":"Macrophage variants in laboratory research: most are well done, but some are RAW","volume":"14","author":"Herb","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.exphem.2026.105384_bib0041","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105384_bib0042","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.0710409","article-title":"Obstacles and opportunities for understanding macrophage polarization","volume":"89","author":"Murray","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0043","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1073\/pnas.1218599110","article-title":"Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production","volume":"110","author":"Michelucci","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105384_bib0044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.2910260208","article-title":"Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)","volume":"26","author":"Tsuchiya","year":"1980","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2018.04.013","article-title":"The bicarbonate transporter SLC4A7 plays a key role in macrophage phagosome acidification","volume":"23","author":"Sedlyarov","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.exphem.2026.105384_bib0046","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2015-05-647032","article-title":"Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X","volume":"127","author":"Muczynski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105384_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2024.113716","article-title":"1,25-dihydroxyvitamin D3 augments low-dose PMA-based monocyte-to-macrophage differentiation in THP-1 cells","volume":"532","author":"Mol","year":"2024","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2026.105384_bib0048","series-title":"The Impact of Food Bioactives on Health: in Vitro and Ex Vivo Models","first-page":"147","article-title":"THP-1 and U937 cells","author":"Chanput","year":"2015"},{"key":"10.1016\/j.exphem.2026.105384_bib0049","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/ijc.32967","article-title":"Major multilevel molecular divergence between THP-1 cells from different biorepositories","volume":"147","author":"Noronha","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278365","article-title":"THP-1 cells transduced with CD16A utilize Fc\u03b3 receptor I and III in the phagocytosis of IgG-sensitized human erythrocytes and platelets","volume":"17","author":"Gil Gonzalez","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2026.105384_bib0051","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jim.2009.03.014","article-title":"Efficient non-viral transfection of THP-1 cells","volume":"344","author":"Schnoor","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2026.105384_bib0052","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-7519-8_4","article-title":"Modeling primary human monocytes with the trans-differentiation cell line BLaER1","volume":"1714","author":"Gaidt","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0053","article-title":"An epigenetic GPI anchor defect impairs TLR4 signaling in the B cell transdifferentiation model for primary human monocytes BLaER1","volume":"11","author":"Wegner","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0054","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.celrep.2017.04.072","article-title":"C\/EBP\u03b1 induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity","volume":"19","author":"Rapino","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/mmi.15142","article-title":"Investigating pyroptosis as a mechanism of L. major cell-to-cell spread in the human BLaER1 infection model","volume":"121","author":"Volkmar","year":"2024","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.exphem.2026.105384_bib0056","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.celrep.2013.03.003","article-title":"C\/EBP\u03b1 induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity","volume":"3","author":"Rapino","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0057","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.stem.2009.10.004","article-title":"A robust and highly efficient immune cell reprogramming system","volume":"5","author":"Bussmann","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0058","first-page":"41","article-title":"The HL60 cell line: a model system for studying human myeloid cell differentiation","volume":"9","author":"Birnie","year":"1988","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.exphem.2026.105384_bib0059","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ijc.2910410324","article-title":"Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes","volume":"41","author":"Ziegler-Heitbrock","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178337","article-title":"The generation, activation, and polarization of monocyte-derived macrophages in human malignancies","volume":"14","author":"Chaintreuil","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117161","article-title":"Potential applications of macrophages in cancer immunotherapy","volume":"178","author":"Sadri","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2026.105384_bib0062","article-title":"Comparison of monocytic cell lines U937 and THP-1 as macrophage models for in vitro studies","volume":"32","author":"Nascimento","year":"2022","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0063","first-page":"55","article-title":"Macrophage based drug delivery: key challenges and strategies","volume":"38","author":"Guo","year":"2024","journal-title":"Bioact Mater"},{"issue":"Suppl 16","key":"10.1016\/j.exphem.2026.105384_bib0064","article-title":"Effect of in vivo engineered CAR-macrophages on physical barriers, tumor regression and immune memory to prevent tumor recurrence","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0065","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCRESAHA.125.326716","article-title":"CAR Macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury","volume":"137","author":"Du","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.exphem.2026.105384_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102610","article-title":"Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors","volume":"61","author":"Zhou","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.exphem.2026.105384_bib0068","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/2159-8290.CD-NB2023-0083","article-title":"In vivo CAR monocytes show efficacy in mice","volume":"14","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2026.105384_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.exphem.2026.105384_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.exphem.2026.105384_bib0071","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105384_bib0072","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426724122","article-title":"In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy","volume":"122","author":"Zhou","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105384_bib0073","doi-asserted-by":"crossref","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.exphem.2026.105384_bib0075","article-title":"In vivo production of CAR T cell: opportunities and challenges","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.exphem.2026.105384_bib0076","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0077","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01563-23","article-title":"Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses","volume":"98","author":"Yang","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.exphem.2026.105384_bib0078","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.3390\/ijms21134808","article-title":"Large-scale production of human iPSC-derived macrophages for drug screening","volume":"21","author":"Gutbier","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0079","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42174-2","article-title":"Efficient gene editing in induced pluripotent stem cells enabled by an inducible adenine base editor with tunable expression","volume":"13","author":"Nandy","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/spmg.19885","article-title":"Cell lines: valuable tools or useless artifacts","volume":"2","author":"Kaur","year":"2012","journal-title":"Spermatogenesis"},{"key":"10.1016\/j.exphem.2026.105384_bib0081","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402760","article-title":"Mass spectrometry\u2013based proteomic exploration of diverse murine macrophage cellular models","volume":"8","author":"Gudgeon","year":"2025","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.exphem.2026.105384_bib0082","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.stemcr.2016.12.020","article-title":"Human induced pluripotent stem cell-derived macrophages share ontogeny with MYB-independent tissue-resident macrophages","volume":"8","author":"Buchrieser","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2026.105384_bib0083","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00353-24","article-title":"Physiologic medium renders human iPSC-derived macrophages permissive for M. tuberculosis by rewiring organelle function and metabolism","volume":"15","author":"Bussi","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.exphem.2026.105384_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243807","article-title":"Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts","volume":"15","author":"Monkley","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2026.105384_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.759558","article-title":"Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells","volume":"12","author":"Netsrithong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0086","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/sctm.20-0242","article-title":"Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product","volume":"10","author":"Jha","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0087","doi-asserted-by":"crossref","first-page":"18","DOI":"10.32607\/20758251-2010-2-2-18-27","article-title":"Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine","volume":"2","author":"Medvedev","year":"2010","journal-title":"Acta Naturae"},{"key":"10.1016\/j.exphem.2026.105384_bib0088","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.ymthe.2021.08.013","article-title":"Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy","volume":"29","author":"Schambach","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0089","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0090","article-title":"Induced pluripotent stem cells: generation methods and a new perspective in COVID-19 research","volume":"10","author":"Karami","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0091","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2217\/rme-2018-0095","article-title":"Quality control guidelines for clinical-grade human induced pluripotent stem cell lines","volume":"13","author":"Sullivan","year":"2018","journal-title":"Regen Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0092","doi-asserted-by":"crossref","first-page":"686","DOI":"10.5966\/sctm.2013-0158","article-title":"Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity","volume":"3","author":"Steichen","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0093","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12015-016-9662-8","article-title":"Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications","volume":"12","author":"Baghbaderani","year":"2016","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0094","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","article-title":"Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products","volume":"38","author":"Sadeqi Nezhad","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.exphem.2026.105384_bib0096","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0097","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.3390\/ijms151017411","article-title":"The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature","volume":"15","author":"Xiong","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0098","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.exphem.2026.105384_bib0099","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","article-title":"Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2","volume":"72","author":"Duan","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2026.105384_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669103","article-title":"CAR macrophages for SARS-CoV-2 immunotherapy","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/path.5585","article-title":"Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity","volume":"253","author":"Niu","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.exphem.2026.105384_bib0102","doi-asserted-by":"crossref","unstructured":"Uenaka T, Napole A, Saha A, et al. Prevention of transgene silencing during human pluripotent stem cell differentiation. bioRxiv 2025. 2025.04.07.647695.","DOI":"10.1101\/2025.04.07.647695"},{"key":"10.1016\/j.exphem.2026.105384_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108287","article-title":"CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells","volume":"26","author":"Vlassis","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.exphem.2026.105384_bib0105","article-title":"Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma","volume":"20","author":"Jin","year":"2023","journal-title":"Immunooncol Technol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0106","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1182\/blood-2022-159752","article-title":"Targeted genomic insertion of cars in iPSC-derived macrophages leads to improved expression and anti-tumor activity","volume":"140","author":"Kong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105384_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2024.195063","article-title":"Human stem cell-specific epigenetic signatures control transgene expression","volume":"1867","author":"Kwak","year":"2024","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"10.1016\/j.exphem.2026.105384_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0112","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/184154","article-title":"Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming","volume":"2012","author":"Kretsovali","year":"2012","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.exphem.2026.105384_bib0113","first-page":"27","article-title":"Adoptive cell therapy from the Dish: potentiating induced pluripotent stem cells","volume":"52","author":"Lindenbergh","year":"2025","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.exphem.2026.105384_bib0114","doi-asserted-by":"crossref","unstructured":"Yoo SP, Yuan X, Engstrom C, et al. Stage-specific CAR-mediated signaling generates na\u00efve-like, TCR-null CAR T cells from induced pluripotent stem cells. bioRxiv 2025. 2024.11.25.624041.","DOI":"10.1101\/2024.11.25.624041"},{"key":"10.1016\/j.exphem.2026.105384_bib0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416087","article-title":"iPSC-derived macrophages: the differentiation protocol affects cell immune characteristics and differentiation trajectories","volume":"23","author":"Klepikova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105384_bib0116","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1002\/cphg.64","article-title":"Efficient differentiation of human pluripotent stem cells to endothelial cells","volume":"98","author":"Gu","year":"2018","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1016\/j.exphem.2026.105384_bib0117","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41556-019-0423-1","article-title":"Eomes and Brachyury control pluripotency exit and germ-layer segregation by changing the chromatin state","volume":"21","author":"Tosic","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0118","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.stemcr.2018.09.013","article-title":"Early human hemogenic endothelium generates primitive and definitive hematopoiesis in vitro","volume":"11","author":"Garcia-Alegria","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2026.105384_bib0119","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2020003969","article-title":"Redundant mechanisms driven independently by RUNX1 and GATA2 for hematopoietic development","volume":"5","author":"Bresciani","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2026.105384_bib0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/cr.2011.138","article-title":"TGF\u03b2 inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy","volume":"22","author":"Wang","year":"2012","journal-title":"Cell Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0121","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.celrep.2012.08.002","article-title":"Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures","volume":"2","author":"Choi","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13619-023-00175-6","article-title":"Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges","volume":"12","author":"Zheng","year":"2023","journal-title":"Cell Regen"},{"key":"10.1016\/j.exphem.2026.105384_bib0123","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1038\/s41598-023-36508-3","article-title":"Induced pluripotent and CD34+\u2009stem cell derived myeloid cells display differential responses to particle and dust mite exposure","volume":"13","author":"Fransen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0124","doi-asserted-by":"crossref","DOI":"10.1634\/stemcells.2008-0922","article-title":"Hematopoietic and endothelial differentiation of human induced pluripotent stem cells","volume":"27","author":"Choi","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2026.105384_bib0125","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/bioengineering9120720","article-title":"Differentiating human pluripotent stem cells to cardiomyocytes using purified extracellular matrix proteins","volume":"9","author":"Barnes","year":"2022","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.exphem.2026.105384_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2017.06.017","article-title":"Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function","volume":"47","author":"Takata","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2026.105384_bib0127","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.stemcr.2019.05.003","article-title":"Differentiation and functional comparison of monocytes and macrophages from hiPSCs with peripheral blood derivatives","volume":"12","author":"Cao","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2026.105384_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.640703","article-title":"Macrophages derived from human induced pluripotent stem cells: the diversity of protocols, future prospects, and outstanding questions","volume":"9","author":"Lyadova","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0129","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2012-06-434407","article-title":"In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells","volume":"121","author":"Amabile","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105384_bib0130","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/mt.2013.71","article-title":"Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol Ther"},{"issue":"158","key":"10.1016\/j.exphem.2026.105384_bib0131","doi-asserted-by":"crossref","DOI":"10.3791\/61038","article-title":"Production and characterization of human macrophages from pluripotent stem cells","author":"Lopez-Yrigoyen","year":"2020","journal-title":"J Vis Exp"},{"key":"10.1016\/j.exphem.2026.105384_bib0132","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41596-021-00654-7","article-title":"Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors","volume":"17","author":"Ackermann","year":"2022","journal-title":"Nat Protoc"},{"key":"10.1016\/j.exphem.2026.105384_bib0133","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1038\/s41467-018-07570-7","article-title":"Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections","volume":"9","author":"Ackermann","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105384_bib0134","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13287-024-03785-2","article-title":"Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions","volume":"15","author":"Ackermann","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0136","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2021-148687","article-title":"Development of chimeric antigen receptor-expressing iPSC-derived macrophages with improved anti-tumor activity","volume":"138","author":"Pouyanfard","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0137","doi-asserted-by":"crossref","first-page":"9238","DOI":"10.1182\/blood-2022-165323","article-title":"The second generation of human iPSC-derived CAR-macrophages for immune cell therapies in liquid and solid tumors","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105384_bib0138","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105384_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105390","article-title":"Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring harbouring Megf10 and CD3\u03b6 from human pluripotent stem cells","volume":"109","author":"Zhen","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.exphem.2026.105384_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151158","article-title":"Generation of chimeric antigen receptor-macrophages by using human induced pluripotent stem cells","volume":"743","author":"Kitajima","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 15","key":"10.1016\/j.exphem.2026.105384_bib0142","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2020.38.15_suppl.3014","article-title":"Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma","volume":"38","author":"Annunziata","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"10.1016\/j.exphem.2026.105384_bib0143","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","article-title":"A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors","volume":"40","author":"Reiss","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.exphem.2026.105384_bib0144","first-page":"116","article-title":"A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0145","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0146","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0147","first-page":"0268","article-title":"Development of FT825\/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression","volume":"11","author":"Hosking","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.exphem.2026.105384_bib0148","article-title":"264 Next-generation off-the-shelf CAR T cell targeting pan-tumor antigen MICA\/B and engineered with immune evasion enables treatment across solid tumors without the need for conditioning chemotherapy","volume":"13","author":"Peralta","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0149","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105384_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105384_bib0151","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1182\/blood-2024-198684","article-title":"Safety and efficacy of FT522, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed\/refractory B-cell lymphoma","volume":"144","author":"Bachanova","year":"2024","journal-title":"Blood"},{"issue":"Suppl 16","key":"10.1016\/j.exphem.2026.105384_bib0152","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/JCO.2024.42.16_suppl.7023","article-title":"Interim results from the ELiPSE-1 study: a phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies","volume":"42","author":"Patel","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0153","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2026.105384_bib0154","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780145","article-title":"Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials","volume":"12","author":"Smirnov","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2025.104762","article-title":"Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies","volume":"146","author":"Ismail","year":"2025","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2026.105384_bib0156","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105384_bib0157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0158","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.exphem.2026.105384_bib0159","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41420-024-02247-1","article-title":"Macrophages in organ fibrosis: from pathogenesis to therapeutic targets","volume":"10","author":"Jiang","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.exphem.2026.105384_bib0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975233","article-title":"Combinatorial suicide gene strategies for the safety of cell therapies","volume":"13","author":"Falcon","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0161","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/0929866526666190503105343","article-title":"NMAAP1 maintains M1 phenotype in macrophages through binding to IP3R and activating calcium-related signaling pathways","volume":"26","author":"Liu","year":"2019","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.exphem.2026.105384_bib0162","doi-asserted-by":"crossref","first-page":"eabj7002","DOI":"10.1126\/sciadv.abj7002","article-title":"Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity","volume":"8","author":"Kamerkar","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.exphem.2026.105384_bib0163","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2026.105384_bib0164","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1189\/jlb.1211639","article-title":"Deletion of TGF-\u03b2 signaling in myeloid cells enhances their anti-tumorigenic properties","volume":"92","author":"Novitskiy","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2026.105384_bib0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J Transl Med"},{"issue":"Suppl 3","key":"10.1016\/j.exphem.2026.105384_bib0166","article-title":"128 Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy","volume":"8","author":"Ohtani","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0167","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3892\/ijmm.2016.2583","article-title":"Effects of IRF1 and IFN-\u03b2 interaction on the M1 polarization of macrophages and its antitumor function","volume":"38","author":"Xie","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.exphem.2026.105384_bib0168","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0169","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2026.105384_bib0170","article-title":"Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review","volume":"2025","author":"Morva","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105384_bib0171","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41421-024-00718-4","article-title":"Targeting cardiac fibrosis with chimeric antigen receptor macrophages","volume":"10","author":"Gao","year":"2024","journal-title":"Cell Discovery"},{"key":"10.1016\/j.exphem.2026.105384_bib0172","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","article-title":"CAR-macrophage therapy alleviates myocardial Ischemia-Reperfusion Injury","volume":"135","author":"Wang","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0173","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models","volume":"80","author":"Dai","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.exphem.2026.105384_bib0174","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41551-025-01387-8","article-title":"Targeting inflammation with chimeric antigen receptor macrophages using a signal switch","volume":"9","author":"Cao","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.exphem.2026.105384_bib0175","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.2147\/OTT.S216355","article-title":"Tumor-associated macrophages (TAMs): a critical activator in ovarian cancer metastasis","volume":"12","author":"Yin","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.exphem.2026.105384_bib0176","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12935-023-02999-3","article-title":"Macrophage\u2019s role in solid tumors: two edges of a sword","volume":"23","author":"Jahandideh","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.exphem.2026.105384_bib0177","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105384_bib0178","article-title":"Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques","volume":"11","author":"Tang","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.exphem.2026.105384_bib0179","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106329","article-title":"Locoregional delivery of CAR-T cells in the clinic","volume":"182","author":"Sagnella","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.exphem.2026.105384_bib0180","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T16:44:05Z","timestamp":1779554645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":179,"alternative-id":["S0301472X26000172"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105384","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105384"}}